Detecting and monitoring longitudinal pathological and clinical changes of Alzheimer's disease using plasma <i>p</i> ‐Tau217

Our findings highlight the advantages of plasma p-tau217 in detecting and monitoring dynamic disease progression. Confirmatory tests and longitudinal tracking are necessary for those with intermediate plasma p-tau217, as they may be at the early AD stage with high risks of rapid disease evolution. This categorized strategy may identify a novel target population for early pathological characteristics studies and interventions in AD. Incorporating high-performance blood p-tau217 tests into clinical trials may improve AD diagnosis and enable larger-scale screening of early-stage patients with suspected AD pathophysiology for anti-amyloid immunotherapies.